ADRIATIC Trial: Durvalumab Consolidation Extends Survival in …
Oct 25, 2024 · Durvalumab consolidation therapy was associated with nearly 2-year longer median overall survival and more than 7-month-longer median progression-free survival compared with placebo in patients with limited-stage SCLC.
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell …
Sep 13, 2024 · Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard...
Imfinzi is first and only immunotherapy to show survival benefit in ...
Jun 2, 2024 · Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
Jun 25, 2024 · The immunotherapy drug durvalumab (Imfinzi) helped people with early-stage small cell lung cancer live longer, according to initial results from a large clinical trial. Durvalumab is a type of immunotherapy called an immune checkpoint inhibitor.
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small …
Jun 25, 2024 · Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.
Interim ADRIATIC Results: Durvalumab Improves ... - ASCO Daily News
Jun 2, 2024 · Interim results from the long-awaited ADRIATIC trial found consolidation treatment with the selective monoclonal antibody durvalumab is associated with statistically significant and clinically meaningful improvements in survival versus placebo among patients with limited-stage small cell lung cancer (LS-SCLC; LBA5).
Perioperative Durvalumab for Resectable Non–Small-Cell Lung …
Oct 23, 2023 · Durvalumab is a selective, high-affinity, human IgG1 monoclonal antibody that inhibits interaction of PD-L1 with PD-1 and CD80 by binding to PD-L1. 28 Findings from the PACIFIC trial have...
FDA approves neoadjuvant/adjuvant durvalumab
On August 15, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent...
FDA Approves Neoadjuvant/Adjuvant Durvalumab for Resectable …
On August 15, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known ...
Durvalumab - latest research news and features - Medical Xpress
Sep 19, 2024 · News on durvalumab. Oncology & Cancer. Adjuvant durvalumab extends survival in small cell lung cancer. For patients with limited-stage small cell lung cancer, adjuvant therapy with...